EM1710E "SGLT 2 Inhibitors Improve CardioRenal Outcomes in DM2 – Get Rid of the Sugar" (IM GR-100617)

Purpose and Overview: Review treatment options for DM2, emphasizing the improved CV and Renal outcomes with SGLT2 Inhibitors.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

At the conclusion of this activity, the participant should be able to:

Appreciate the rising incidence of DM2 and increased CV risks with DM2
Recall the lack of CV outcome benefits with SU’s, TZD’s, DPP4 inhibitors.
Appreciate the improved CV and Renal outcomes with SGLT2 Inhibitors, as well as GLP1 agonists

Course summary

Available credit:

Course opens:

10/11/2017

Course expires:

11/10/2017

Cost:

$0.00

Part of:

Photo: David S. Balis, M.D. David S. Balis, M.D.
Professor of Internal Medicine
Division of General Internal Medicine

Cost:

$0.00

Please login or create an account to take this course.

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome